Loading...
XNYS
ZTS
Market cap53bUSD
Dec 04, Last price  
120.41USD
1D
-1.76%
1Q
-21.46%
Jan 2017
124.94%
IPO
288.17%
Name

Zoetis Inc

Chart & Performance

D1W1MN
XNYS:ZTS chart
P/E
21.35
P/S
5.73
EPS
5.64
Div Yield, %
1.08%
Shrs. gr., 5y
-1.14%
Rev. gr., 5y
8.14%
Revenues
9.26b
+8.33%
2,760,000,0003,582,000,0004,233,000,0004,336,000,0004,561,000,0004,785,000,0004,765,000,0004,888,000,0005,307,000,0005,825,000,0006,260,000,0006,675,000,0007,776,000,0008,080,000,0008,544,000,0009,256,000,000
Net income
2.49b
+6.06%
-100,000,000110,000,000245,000,000436,000,000504,000,000583,000,000339,000,000821,000,000864,000,0001,428,000,0001,500,000,0001,638,000,0002,037,000,0002,114,000,0002,344,000,0002,486,000,000
CFO
2.95b
+25.50%
98,000,000254,000,000497,000,000454,000,000681,000,000626,000,000664,000,000713,000,0001,346,000,0001,790,000,0001,795,000,0002,126,000,0002,213,000,0001,912,000,0002,353,000,0002,953,000,000
Dividend
Apr 21, 20250.5 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
IPO date
Feb 01, 2013
Employees
13,800
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT